Australia’s New South Wales (NSW) Government has revealed plans to establish a new children’s hospice, Mounties Care Cottage, within The Children’s Hospital at Westmead.
This facility in Western Sydney aims to provide a home-like environment for children with life-limiting illnesses and their families, offering symptom management, respite and end-of-life care.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
NSW Health Minister Ryan Park said: “This is an incredibly important project for Western Sydney, which will provide a crucial support for children and their families from the local area, and beyond.”
Mounties Care Cottage will be the second children’s hospice in the state.
It will be supported by a contribution of over A$20m ($12.84m) from the Minns Labor Government.
Additionally, Mounties Group will donate A$13m over ten years via the Sydney Children’s Hospitals Foundation.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe hospice is designed to be a space for families, featuring an on-site kitchen, dining area, and private access to gardens and play areas.
It will integrate with other paediatric services at The Children’s Hospital at Westmead, such as oncology and intensive care, to ensure patient-centred care.
Mounties Care Cottage will complement the services provided by Bear Cottage under the Sydney Children’s Hospitals Network, expanding the care options for families throughout NSW.
The planning and design phase for this establishment is scheduled to begin this year.
Mounties Group CEO Dale Hunt said: “Mounties Group is so proud to continue its advocacy and support for Greater Western Sydney families with terminally ill children to access specialist paediatric palliative care in their local area.”
Recently, the NSW government allocated A$180,000 for the enhancement of treatment and support for individuals with macular disease.
